The antimicrobial effects and metabolomic footprinting of carboxyl-capped bismuth nanoparticles against helicobacter pylori

Applied Biochemistry and Biotechnology

Volumn 172, Issue 2, 2014, Pages 570-579

  Nazari, P ^a   Dowlatabadi Bazaz, R ^b   Mofid, M R ^c   Pourmand, M R ^a   Daryani, N E ^d   Faramarzi, M A ^a   Sepehrizadeh, Z ^a   Shahverdi, A R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biosynthesis; Bismuth; Helicobacter pylori; Metabolomics; Nanoparticle

Indexed keywords

ANTI-BACTERIAL AGENTS; BISMUTH; CARBOXYLIC ACIDS; HELICOBACTER PYLORI; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOMICS; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; SPECTROPHOTOMETRY, INFRARED; ULTRASONICS;

EID: 84894471218     PISSN: 02732289     EISSN: 15590291     Source Type: Journal    
DOI: 10.1007/s12010-013-0571-x     Document Type: Article

References (24)

1. Boisseau, P.; Loubaton, B. (2011). Nanomedicine, nanotechnology in medicine. CR Physics, 12, 620-636.
2. Roco, M. C. (2003). Nanotechnology: convergence with modern biology and medicine. Current Opinion Biotechnology, 14, 337-346.
3. Sahoo, S. K.; Parveen, S.; Panda, J. J. (2007). The present and future of nanotechnology in human health care. Nanomedicine: Nanotechnology, Biology, and Medicine, 3, 20-31.
4. Arvizo, R. R.; Bhattacharyya, S.; Kudgus, R. A.; Giri, K.; Bhattacharya, R.; Mukherjee, P. (2012). Intrinsic therapeutic applications of noble metal nanoparticles: past, present, and future. Chemical Society Reviews, 41, 2943-2970.
5. Peng, H. I.; Miller, B. L. (2010). Recent advancements in optical DNA biosensors: exploiting the plasmonic effects of metal nanoparticles. Analyst, 136, 436-447.
6. Sau, T. K.; Rogach, A. L.; Jäckel, F.; Klar, T. A.; Feldmann, J. (2010). Properties and applications of colloidal nonspherical noble metal nanoparticles. Advanced Materials, 22, 1805-1825.
7. Sokolov, K.; Tam, J.; Tam, J.; Travis, K.; Larson, T.; Aaron, J.; et al. (2009). Cancer imaging and therapy with metal nanoparticles. Conf Proc IEEE Eng Med Biol Soc, 2009, 2005-2007.
8. Dykman, L.; Khlebtsov, N. (2012). Gold nanoparticles in biomedical applications: recent advances and perspectives. Chemical Society Reviews, 41, 2256-2282.
9. Wang, D.; Taylor, E. W.; Wang, Y.; Wan, X.; Zhang, J. (2012). Encapsulated nanoepigallocatechin-3-gallate and elemental selenium nanoparticles as paradigms for nanochemoprevention. International Journal of Nanomedicine, 7, 1711-1721.
10. Chen, R.; Cheng, G.; So, M. H.; Wu, J.; Lu, Z.; Che, C. M.; et al. (2010). Bismuth subcarbonate nanoparticles fabricated by water-in-oil microemulsion-assisted hydrothermal process exhibit anti-Helicobacter pylori properties. Materials Research Bulletin, 45, 654-658.
11. Chen, R.; So, M. H.; Yang, J.; Deng, F.; Che, C. M.; Sun, H. Z. (2006). Fabrication of bismuth subcarbonate nanotube arrays from bismuth citrate. Chemical Communications, 21, 2265-2267.
12. Sox, T. E.; Olson, C. A. (1998). Binding and killing of bacteria by bismuth subsalicylate. Antimicrobial Agents and Chemotherapy, 33, 2075-2082.
13. Stoltenberg, M.; Martiny, M.; Sorensen, K.; Rungby, J.; Krogfelt, K. A. (2001). Histochemical tracing of bismuth in Helicobacter pylori after in vitro exposure to bismuth citrate. Scandinavian Journal of Gastroenterology, 2, 144-148.
14. Mahony, D. E.; Lim-Morrison, S.; Bryden, L.; Faulkner, G.; Hoffman, P. S.; Agocs, L.; et al. (1999). Antimicrobial activities of synthetic bismuth compounds against Clostridium difficile. Antimicrobiol Agents Chemother, 43, 582-588.
15. Salih, B. A. (2009). Helicobacter pylori infection in developing countries: the burden for how long? Saudi Journal of Gastroenterology, 15, 201-207.
16. Andersen, L. P.; Colding, H.; Kristiansen, J. E. (2000). Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate. International Journal of Antimicrobial Agents, 14, 231-234.
17. Chuah, S. K.; Tsay, F. W.; Hsu, P. I.; Wu, D. C. (2011). A new look at anti-Helicobacter pylori therapy. World Journal of Gastroenterology, 17, 3971-3975.
18. O'Connor, A.; Gisbert, J. P.; McNamara, D.; O'Morain, C. (2011). Treatment of Helicobacter pylori infection 2011. Helicobacter, 16(Suppl 1), 53-58.
19. P. Nazari, M. A. Faramarzi, Z. Sepehrizadeh, M. R. Mofid, R. D. Bazaz, A. R. Shahverdi. Biosynthesis of bismuth nanoparticles using Serratia marcescens isolated from the Caspian Sea and their characterization. IET Nanobiotechnology, 6: 58-62.
20. McLaren, A. (1997). Methods in molecular medicine. In C. Clayton & H. Mobley (Eds.), In vitro susceptibility testing of H. pylori (Vol. 8, pp. 41-51). Totowa:NJ: Humana Press Inc.
21. European committee for antimicrobial susceptibility testing (EUCAST). (2000). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clinical Microbiology and Infection, 6, 509-515.
22. Stratton, C. W.; Warner, R.; Coudron, P. E.; Lilly, N. (1999). Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts. The Journal of Antimicrobial Chemotherapy, 43, 659-666.
23. Chen, Z.; Zhou, Q.; Ge, R. (2012). Inhibition of fumarase by bismuth(III): implications for the tricarboxylic acid cycle as a potential target of bismuth drugs in Helicobacter pylori. BioMetals, 25, 95-102.
24. Ge, R.; Sun, X.; Gu, Q.; Watt, R. M.; Tanner, J. A.; Wong, B. C.; et al. (2007). A proteomic approach for the identification of bismuth binding proteins in Helicobacter pylori. Journal of Biological Inorganic Chemistry, 12, 831-842.